Literature DB >> 8442397

Motor impairment in Wilson's disease, II: Slowness of speech.

H Hefter1, G Arendt, W Stremmel, H J Freund.   

Abstract

The maximal syllable production rate (MSPR) and the ability to reproduce a given target frequency in the 1 to 8 Hz range by repeating the short syllable "ta" was tested in 20 patients with Wilson's disease (WD) and 20 normal subjects. MSPR was significantly reduced in the WD-patients. In the 1 to 5 Hz range normal subjects as well as WD-patients tended to produce slightly higher frequencies than the target frequencies. This hastening was maximal in normals between 4 to 5 Hz whereas in the WD-patients hastening mainly occurred between 3 to 4 Hz. The test results showed a considerable variation across the patients. This variation can be interpreted on the basis of the theory of coupled oscillators. Comparison of speech and finger movements revealed a highly significant correlation between MSPR and the highest possible frequency of voluntary alternating index finger movements. As an application of the presented test treatment effects on speech movements were demonstrated.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8442397     DOI: 10.1111/j.1600-0404.1993.tb04093.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

Review 1.  Clinical presentations of Wilson disease.

Authors:  Samuel Shribman; Thomas T Warner; James S Dooley
Journal:  Ann Transl Med       Date:  2019-04

2.  Analysis of Single-Leg Hopping in Long-Term Treated Patients with Neurological Wilson's Disease: A Controlled Pilot Study.

Authors:  Harald Hefter; Sara Samadzadeh; Dietmar Rosenthal; Osman Tezayak
Journal:  Medicina (Kaunas)       Date:  2022-02-07       Impact factor: 2.430

3.  Dystonic Dysarthria in Wilson Disease: Efficacy of Zolpidem.

Authors:  Aurélia Poujois; Michaela Pernon; Jean-Marc Trocello; France Woimant
Journal:  Front Neurol       Date:  2017-10-31       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.